Symone Hopkins
Internal Medicine · Richmond, VANPI 1881255602
Payments from drug & device makers
Across 121 payments — averaging $49.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$541
- AbbVie$529
- Boston Scientific$524
- Novo Nordisk$453
- Bayer$376
- Phathom Pharmaceuticals, Inc.$248
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,033100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 9 | $541 |
| AbbVie | 12 | $529 |
| Boston Scientific | 6 | $524 |
| Novo Nordisk | 19 | $453 |
| Bayer | 5 | $376 |
| Phathom Pharmaceuticals, Inc. | 2 | $248 |
| Johnson & Johnson | 2 | $213 |
| Lilly USA, LLC | 6 | $213 |
| AstraZeneca | 7 | $192 |
| Biogen | 2 | $161 |
| Dexcom, Inc. | 2 | $160 |
| Edwards Lifesciences | 3 | $158 |
| SK Life Science, Inc. | 2 | $157 |
| Pfizer | 4 | $152 |
| Xeris Pharmaceuticals, Inc. | 2 | $146 |
| Inspire Medical Systems, Inc. | 1 | $139 |
| Corium, LLC | 2 | $134 |
| Abiomed | 1 | $132 |
| Biohaven Pharmaceuticals, Inc. | 1 | $123 |
| Eisai Inc. | 1 | $122 |
| Otsuka America Pharmaceutical, Inc. | 1 | $122 |
| Alnylam Pharmaceuticals Inc. | 1 | $120 |
| Atricure, Inc. | 1 | $110 |
| Vanda Pharmaceuticals Inc. | 1 | $108 |
| Halozyme Inc | 1 | $103 |
| Silk Road Medical, Inc. | 1 | $90 |
| Lundbeck LLC | 2 | $85 |
| GSK | 4 | $63 |
| Mylan Specialty L.p. | 3 | $55 |
| Novartis | 3 | $46 |
| Philips North America LLC | 2 | $42 |
| Exact Sciences | 2 | $41 |
| Boehringer Ingelheim | 2 | $35 |
| UCB, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Merck | 1 | $20 |
| Insightec,inc | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
| Augmedics Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$347
- Repatha$259
- VOQUEZNA$248
- QULIPTA$239
- NURTEC ODT$227
- DEXCOM G7 GSS (161)$142
- Inspire$139
- Edwards SAPIEN 3 Transcatheter Heart Valve$137
- WATCHMAN Access System$135
- Impella$132
- XARELTO$125
- XCOPRI$124
- DALVANCE$124
- Leqembi$122
- REXULTI$122
- GVOKE HYPOPEN$122
- AMVUTTRA$120
- MOUNJARO$120
- WATCHMAN FLX$120
- UBRELVY$118
How this compares
$6,033 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 66 | $87,516 |
| EliquisApixaban | 69 | $70,661 |
| JardianceEmpagliflozin | 32 | $52,923 |
| OzempicSemaglutide | 43 | $46,856 |
| PrezcobixDarunavir/Cobicistat | 12 | $29,055 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $26,004 |
| XareltoRivaroxaban | 20 | $21,572 |
| MounjaroTirzepatide | 17 | $21,390 |
| FarxigaDapagliflozin Propanediol | 16 | $18,029 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $11,426 |
| JanuviaSitagliptin Phosphate | 13 | $9,110 |
| RestasisCyclosporine | 12 | $8,036 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $6,756 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $4,591 |
| Atomoxetine Hcl | 12 | $4,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $213 | $108,90683 claims |
| PfizerEliquis | $152 | $70,66169 claims |
| Boehringer IngelheimJardiance | $35 | $52,92332 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $213 | $50,62732 claims |
| Novo NordiskOzempic | $453 | $46,85643 claims |
| AstraZenecaFarxiga | $192 | $18,02916 claims |
| MerckJanuvia, Janumet | $20 | $15,86625 claims |
| GSKBreo Ellipta | $63 | $11,42617 claims |
| AbbVieRestasis, Synthroid | $529 | $9,75330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Richmond
- Leroy VaughanRichmond$20.8M
- Andrew PoklepovicRichmond$4.6M
- Richard JacksonRichmond$2.5M
- Lawrence SchwartzRichmond$2.4M
- John HoekstraRichmond$344K
- Franklin ZieveRichmond$337K
- Wally SmithRichmond$333K
- Thokozeni LipatoRichmond$247K
- John BarrettRichmond$217K
- Alan DowRichmond$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.